Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib, Thalidomide, and Dexamethasone Maintenance After Stem Cell Transplant in Multiple Myeloma
NCT00792142Phase 2Completed
- Sponsor
- City of Hope
- Start
- Mar 2008
- Primary completion
- Apr 2014
- Modality
- Modified Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, thalidomide and dexamethasone in multiple myeloma (MM), sponsored by City of Hope. Primary endpoints: Number of Participants With Adverse Events at 4 months and One Year Overall Survival at 1 year. Started Mar 2008; status: completed.
02
Drugs
bortezomibthalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00792142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00792142.